Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism SARS-CoV-2 PLpro inhibitors(SARS-CoV-2 PLpro inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC28H34N4O2S |
InChIKeyJZRRCGQQCZGHEA-AUSIDOKSSA-N |
CAS Registry2817811-08-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Coronavirus Infections | Preclinical | US | 05 Aug 2024 |